Approved Formulary
Add Formweb to your mobile device
Approved Formulary
HIGH ALERT: Please read the COMMENTS very carefully.
Black Box Warning: Addiction, Abuse, and Misuse; Life -Threatening Respiratory Depression; Neonatal Opioid Withdrawal Syndrome; Cytoshrome P450 3A4 interaction; Risks from Concomitant Use with CNS Depresssants and Monoamine Oxidase (MOA) Inhibi
Search results for:
MEPERIDINE - ORAL FORMULATIONS ARE NONFORMULARY
MEPERIDINE - ORAL FORMULATIONS ARE NONFORMULARY
| Drug Name | Form | Strength | Non-Formulary | Notes |
|---|---|---|---|---|
| MEPERIDINE HYDROCHLORIDE | INJECTION | 10 mg/ml | ||
| MEPERIDINE HYDROCHLORIDE | INJECTION | 25 mg/ml | ||
| MEPERIDINE HYDROCHLORIDE | INJECTION | 50 mg/ml | ||
| MEPERIDINE HYDROCHLORIDE | INJECTION | 75 mg/ml | ||
| MEPERIDINE HYDROCHLORIDE | INJECTION | 100 mg/ml | ||
| MEPERIDINE HYDROCHLORIDE | SYRUP | 50 mg/5 ml | ||
| DEMEROL | TABLET | Not stocked |
View Other Therapeutic Options: Opioid Agonists:
280808
High Alert Drug
Last updated: Aug. 30, 2018
- Black Box Warning: Addiction, Abuse, and Misuse; Life -Threatening Respiratory Depression; Neonatal Opioid Withdrawal Syndrome; Cytoshrome P450 3A4 interaction; Risks from Concomitant Use with CNS Depresssants and Monoamine Oxidase (MOA) Inhibi
Double-checks for appropriateness of drug/dose/pump setting/line placement must be performed during PCA/Epidural use.
Automatic stop order of 48 hours.
Oral formulations are not stocked at Genesis.
The High Risk/High Alert Medication Policy may be found by using the search function in Policies and Procedures